IP Library Granted Patent US 9,616,101
Granted Patent B2
US 9,616,101 · App. 14/413,066 · Granted Apr 11, 2017

Differentiation marker and differentiation control of eye cell

Inventors: Takahiro Nakamura (Kyotanabe, JP); Noriko Koizumi (Kyotanabe, JP); Naoki Okumura (Kyotanabe, JP); Shigeru Kinoshita (Kyoto, JP); Kana Tominaga (Kyoto, JP); Satoshi Kawasaki (Kyoto, JP)
Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION; THE DOSHISHA; SENJU PHARMACEUTICAL CO., LTD.
A61K38/1709A61K35/30A61K48/00C07K14/705C12N5/0621C12Q1/6881G01N33/56966A61K38/00C12N2501/40C12N2501/415C12Q2600/158G01N2333/726G01N2800/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,101
App. No.
14/413,066
Granted
Apr 11, 2017
Kind
B2
Abstract

The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.

Claims (13)

1. A method for suppressing morphological change of a cultured corneal endothelial cell, comprising contacting one or more R-spondins with the corneal endothelial cell, wherein the R-spondins comprise R-spondin 1.

2. The method according to claim 1 , wherein the corneal endothelial cell is a cell which does not proliferate in the stationary state.

3. The method according to claim 1 , wherein the corneal endothelial cell comprises a corneal endothelial cell of a primate.

4. The method according to claim 1 , wherein the corneal endothelial cell comprises a human corneal endothelial cell.

5. The method according to claim 1 , wherein the corneal endothelial cell is in the confluent state.

6. The method according to claim 1 , wherein the corneal endothelial cell is provided in the form of a corneal tissue.

7. A method for suppressing morphological change and promoting proliferation of a cultured corneal endothelial cell, comprising contacting R-spondins with the corneal endothelial cell, wherein the R-spondins comprise R-spondin 1.

8. The method according to claim 7 , wherein the R-spondins further comprise an R-spondin selected from R-spondin-2, R-spondin 3 and R-spondin 4.

9. The method according to claim 7 , wherein the corneal endothelial cell is a cell which does not proliferate in the stationary state.

10. The method according to claim 7 , wherein the corneal endothelial cell comprises a corneal endothelial cell of a primate.

11. The method according to claim 7 , wherein the corneal endothelial cell comprises a human corneal endothelial cell.

12. The method according to claim 7 , wherein the corneal endothelial cell is in the confluent state.

13. The method according to claim 7 , wherein the corneal endothelial cell is provided in the form of a corneal tissue.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2015
From: NAKAMURA, TAKAHIRO; KOIZUMI, NORIKO; OKUMURA, NAOKI; KINOSHITA, SHIGERU; TOMINAGA, KANA; KAWASAKI, SATOSHI
To: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION; THE DOSHISHA; SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 035241/0138 →
Priority Claims (2)
JP 2012-152960 · Jul 6, 2012 · national
JP 2013-016848 · Jan 31, 2013 · national
Continuity (1)
Related Publication 20150202256A1 · Jul 23, 2015